SEP 06, 2015 2:29 PM PDT

Aspirin and Cancer

WRITTEN BY: Ilene Schneider
Immunotherapy is powerful, and British researchers have found a way to make it even more so. By giving cancer patients aspirin at the same time as they receive immunotherapy, clinicians can dramatically boost the effectiveness of the treatment, according to new research published in the journal Cell and reported in Drug Discovery & Development
Aspirin boosts effects of chemotherapy. 
Funded by Cancer Research UK, a group of researchers at the Francis Crick Institute demonstrated that skin, breast and bowel cancer cells often produce large amounts of prostaglandin E2 (PGE2). This molecule interferes with the immune system's usual response to attack faulty cells, which enables cancer to hide. “It is a trick that allows the tumor to thrive and may explain why some immunotherapy treatments have not been as effective as hoped,” according to Cancer Research UK.
 
Aspirin, which is part of a group of molecules called COX inhibitors, can halt the production of PGE2 and assist in reawakening the immune system. By combining immunotherapy with aspirin or other COX inhibitors, the researchers could significantly slow down bowel and melanoma skin cancer growth in mice, as compared to immunotherapy alone.
 
According to one of the study authors, Professor Caetano Reis e Sousa, who is senior group leader at the Francis Crick Institute, "We've added to the growing evidence that some cancers produce PGE2 as a way of escaping the immune system. If you can take away cancer cells' ability to make PGE2, you effectively lift this protective barrier and unleash the full power of the immune system. Giving patients COX inhibitors like aspirin at the same time as immunotherapy could potentially make a huge difference to the benefit they get from treatment. It's still early work, but this could help make cancer immunotherapy even more effective, delivering life-changing results for patients."
 
As Professor Peter Johnson, Cancer Research UK's chief clinician, explained, "PGE2 acts on many different cells in our body, and this study suggests that one of these actions is to tell our immune system to ignore cancer cells. Once you stop the cancer cells from producing it, the immune system switches back to 'kill mode' and attacks the tumor. This research was carried out in mice, so there is still some way to go before we will see patients being given COX inhibitors as part of their treatment. But it's an exciting finding that could offer a simple way to dramatically improve the response to treatment in a range of cancers."
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
MAR 28, 2020
Cancer
MAR 28, 2020
The Not So Minor Genetic Players in Head and Neck Cancers
Head and neck squamous cell carcinomas (HNSCC) are among the most prevalent cancers among smokers, linked to alcohol con ...
APR 06, 2020
Cancer
APR 06, 2020
Should we tell people about their cancer diagnoses?
While it might seem obvious to some cultures, sharing a patient’s diagnosis with him/her is not necessarily the no ...
APR 27, 2020
Cancer
APR 27, 2020
The Tumor Suppressor and its Regulator: An Indirect Oncogene
Oncogenes, mutations in genes that promote cancer growth, have long been easy targets for cancer research due to the dir ...
APR 29, 2020
Immunology
APR 29, 2020
New Immune Cell Discovered in Mammary Ducts
Dubbed “ductal macrophages,” newly discovered immune cells found in breast tissue offer fresh promise for fu ...
MAY 04, 2020
Cancer
MAY 04, 2020
A Retroactive Study Finds an Immunotherapy Effective as a Third-Line Therapy
Cancer is a particularly persistent disease. Many therapies are composed of one or more different treatments. These trea ...
MAY 25, 2020
Genetics & Genomics
MAY 25, 2020
FDA Approves the First Treatment for Neurofibromatosis 1
In a major breakthrough, the Food and Drug Administration has approved a treatment for a genetic disorder called neurofi ...
Loading Comments...